HARMONi-GI3 Clinical Study

What is the purpose of this clinical study?

The purpose of this phase 3 clinical study is to determine whether the combination of ivonescimab with chemotherapy improves the length of time patients live without their cancer getting worse after starting treatment (PFS or progression-free survival) compared to bevacizumab combined with chemotherapy.

What is the clinical trial drug, ivonescimab?

Ivonescimab is an investigational treatment, which works by blocking two separate targets in the body; blocking these targets may decrease the cancer cells' ability to live, grow and spread.

Are you elegible for this clinical study?

• You may be eligible if you have been diagnosed with metastatic CRC and have not received any prior treatment.
  
  
• Please talk with your doctor to determine if you are eligible.

If you are in the clinical study, will you receive ivonescimab?

• You will be randomly assigned to one of two treatment groups.
• Half the patients will be assigned to receive ivonescimab and chemotherapy and the other half will receive bevacizumab and chemotherapy.
• Bevacizumab is a medicine that works by blocking the blood supply to the tumor that it needs to grow.

If you are eligible, what is involved?

Your doctor will provide you with additional information but here are a few things to know:

• Once enrolled in the clinical study, you will visit the clinic every two weeks for infusions (drug delivered directly to the bloodstream) that may continue up to 24 months.

• You will receive regular blood tests and scans of your tumor.

• You will be regularly asked about any side effects or safety concerns you have.